1. |
Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69: 896-904.
DOI
PMID
|
2. |
Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and its management. Nutr Clin Pract 2020; 35: 72-84.
DOI
PMID
|
3. |
Park M, Yoo JH, Lee YS, et al. Lonicera caerulea extract attenuates Non-alcoholic fatty liver disease in free fatty acid-induced HepG 2 hepatocytes and in high fat diet-fed mice. Nutrients 2019; 11: 494.
DOI
URL
|
4. |
Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD)-pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev 2017; 49: 197-211.
DOI
PMID
|
5. |
Yang RX, Pan Q, Liu XL, et al. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis. Lipids Health Dis 2019; 18: 179.
DOI
|
6. |
Yang SJ, Qin XQ, Wang JY. Cigu Xiaozhi capsule in treating nonalcoholic fatty liver of phlegmy wet resistance type. Zhong Hua Zhong Xi Yi Jie He Xiao Hua Za Zhi 2017; 25: 6-11.
|
7. |
Yang SJ. Influence of Cigu Xiaozhi pill on serum Fe and TGF-β1 in nonalcoholic fatty liver disease rat. The 4th China TCM Science and Technology Achievement Forum proceedings. Shenyang: Zhong Hua Zhong Yi Yao Xue Hui, 2014: 49-53.
|
8. |
Su M, Cao D, Wang Z, et al. Fatty acid synthase inhibitor platensimycin intervenes the development of nonalcoholic fatty liver disease in a mouse model. Biomedicines 2021; 10: 5.
DOI
URL
|
9. |
Li M, Xu C, Shi J, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. Gut 2018; 67: 2169-80.
DOI
URL
|
10. |
Kumar DP, Caffrey R, Marioneaux J, et al. The PPAR α/γ agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of Nonalcoholic fatty liver disease. Sci Rep 2020; 10: 9330.
DOI
PMID
|
11. |
Shi DD, Fu YQ. Study on the etiology and pathogenesis of non-alcoholic fatty liver in Traditional Chinese Medicine. Jilin Zhong Yi Yao Za Zhi 2012; 32: 545-6.
|
12. |
Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nature reviews Cancer 2018; 18: 33-50.
DOI
PMID
|
13. |
Nikolova-Karakashian M. Sphingolipids at the crossroads of NAFLD and senescence. Adv Cancer Res 2018; 140: 155-90.
DOI
PMID
|
14. |
Wasilewska N, Bobrus-Chociej A, Harasim-Symbor E, et al. Increased serum concentration of ceramides in obese childrenwith nonalcoholic fatty liver disease. Lipids Health Dis 2018; 17: 216.
DOI
PMID
|
15. |
Apostolopoulou M, Gordillo R, Koliaki C, et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care 2018; 41: 1235-43.
DOI
PMID
|
16. |
Hammerschmidt P, Ostkotte D, Nolte H, et al. Cer S6-derived sphingolipids interact with mff and promote mitochondrial fragmentation in obesity. Cell 2019; 177: 1536-52.
DOI
PMID
|
17. |
Kim YR, Lee EJ, Shin KO, et al. Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases. Exp Mol Med 2019; 51: 1-16.
DOI
PMID
|
18. |
Kanda T, Matsuoka S, Yamazaki M, et al. Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol 2018; 24: 2661-72.
DOI
URL
|
19. |
Mathias S, Pe a LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J 1998, 335: 465-80.
DOI
URL
|
20. |
Jiang M, Li C, Liu Q, et al. Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease. Front Endocrinol (Lausanne) 2019; 10: 665.
DOI
URL
|
21. |
Simon J, Ouro A, Ala-Ibanibo L, et al. Sphingolipids in Non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover. Int J Mol Sci 2019; 21: 40.
DOI
URL
|
22. |
Hao T, Tian HM. Effects of liraglutide on hepatocyte apoptosis and Bcl-2/Bax, Caspase-9 expression in non-alcoholic steatohep-atitis C57 mice. Sichuan Yi Xue Za Zhi 2020; 41: 271-5.
|
23. |
Colombini M. Ceramide channels and mitochondrial outer membrane permeability. J Bioenerg Biomembr 2017; 49: 57-64.
DOI
PMID
|
24. |
Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 5159-65.
DOI
PMID
|